Search for: "Upjohn Co. v. United States" Results 41 - 60 of 92
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
26 Dec 2013, 1:27 pm
One of the most contentious and complicated emerging issues of corporate law in the United States is the issue of attorney client privilege when it is asserted by an entity. [read post]
19 Sep 2013, 9:53 am by Bexis
  In the consultation report of the neurologist states: “Neurontin is wholly appropriate in this patient. [read post]
5 Jul 2013, 5:00 am by Bexis
Surgidev Corp., 899 P.2d 576, 591 (N.M. 1995) (“evidence of compliance with FDA regulations was properly submitted to the jury for consideration”); United Blood Services v. [read post]
28 Feb 2013, 8:10 am by Bexis
Upjohn Co., 625 P.2d 1192, 1195 (N.M. [read post]
21 Nov 2012, 5:00 am by Bexis
Merck & Co.,, No. 267003, 2006 WL 1628516, at *3 (Mich. [read post]
4 Apr 2012, 9:06 am by William McGrath
The Government also described the interview process with defendants, pointing out that counsel for the company gave the employees warning under Upjohn Co. v. [read post]
2 Jun 2011, 12:46 pm by Bexis
Farnes, 697 So.2d 825, 827 (Fla. 1997); Upjohn Co. v. [read post]
28 Apr 2011, 3:18 pm by Bexis
 At least the state of the art at the time of the plaintiff’s use applies – unknown and later discovered risks are irrelevant. [read post]